<div id="readability-page-1"><p>Analyst Yun Zhong of Wedbush maintained a Buy rating on Passage Bio, retaining the price target of $32.00.</p><h3>Claim 30% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Yun Zhong has given his Buy rating due to a combination of factors, including encouraging biomarker data from the ongoing upliFT-D trial in FTD-GRN and a still-manageable development path despite new regulatory hurdles. The Phase 1/2 results show robust and durable CSF PRGN expression at both tested doses, along with consistent declines in plasma NfL and vMRI evidence of slowed brain atrophy in less advanced patients, which collectively support the potential for meaningful clinical benefit.</p> <p>At the same time, the company’s strengthened financial position, with projected cash runway into the first quarter of 2027, reduces near-term financing risk and provides capacity to respond to the FDA’s demand for a randomized controlled registration study. While the new trial design will require more patients, longer follow-up, and additional operational work, limited competition for FTD patients following program exits by other sponsors could facilitate enrollment and preserve Passage Bio’s strategic positioning in this indication.</p> <p>In another report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $23.00 price target.</p></div>

PASG

IBBQ

SBIO

LABU

<p>Analyst Yun Zhong of Wedbush reaffirmed a Buy rating on Passage Bio with a price target of $32.00, citing positive biomarker data from the upliFT-D trial in FTD-GRN and a solid cash runway extending into Q1 2027. The Phase 1/2 results indicate significant clinical benefits, while the company's financial stability mitigates near-term financing risks. Canaccord Genuity also maintained a Buy rating with a $23.00 price target, highlighting limited competition in the FTD space as a strategic advantage for Passage Bio.</p>

Tip Ranks

Passage Bio

SPDR S&P Biotech

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Buy Rating Reaffirmed on Encouraging upliFT-D Biomarker Data and Solid Cash Runway Supporting Expanded FTD-GRN Trial